Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bone marrow mononuclear cells · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Intervention | EXPERIMENTAL | Dose of bone marrow mononuclear cells: 5-7 x 108 total cells |
| Name | Type | Description |
|---|---|---|
| Bone marrow mononuclear cells | OTHER | Intracoronary infusion of autologous bone marrow-derived mononuclear cells |
Inclusion Criteria: 1. Aged between 18 and 80 years. 2. Patients diagnosed with Chronic anterior myocardial infarction (more than 6 months from the acute episode) with symptoms and / or signs of heart failure. 3. Left ventricular ejection fraction (LVEF)\<45% and distensibility changes. 4. Complete...
Bone marrow mononuclear cells are being investigated for the treatment of chronic myocardial ischemia, a condition where the heart muscle does not receive enough oxygen-rich blood. The therapy is administered via intracoronary infusion in patients who have previously experienced a myocardial infarction, with the goal of improving blood flow to the affected heart tissue.
Bone marrow mononuclear cells are being developed by Design Therapeutics, Inc., a biopharmaceutical company publicly traded under the ticker symbol DSGN. The company is conducting clinical research to evaluate the safety and efficacy of this cell-based therapy for patients with chronic myocardial ischemia.
Bone marrow mononuclear cells are in Phase 2 clinical development for chronic myocardial ischemia. The therapy is investigational and has not yet been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its potential in treating this cardiovascular condition.
Bone marrow mononuclear cells have been studied in one completed Phase 2 clinical trial registered as NCT01454323. This trial, titled 'Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction,' enrolled 20 participants in Spain and evaluated the therapy in adults aged 18 years and older with chronic myocardial ischemia.
Bone marrow mononuclear cells are a specific cell population derived from bone marrow that includes various cell types, such as stem cells and progenitor cells. While they are related to bone marrow stem cells, they represent a broader mixture of cells. The therapy is being studied for its potential to treat chronic myocardial ischemia.